|
1
|
Hollis RL and Gourley C: Genetic and
molecular changes in ovarian cancer. Cancer Biol Med. 13:236–247.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Doubeni CA, Doubeni AR and Myers AE:
Diagnosis and management of ovarian cancer. Am Fam Physician.
93:937–944. 2016.PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tsilidis KK, Allen NE, Key TJ, Dossus L,
Kaaks R, Bakken K, Lund E, Fournier A, Dahm CC, Overvad K, et al:
Menopausal hormone therapy and risk of ovarian cancer in the
European prospective investigation into cancer and nutrition.
Cancer Causes Control. 22:1075–1084. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cunat S, Hoffmann P and Pujol P: Estrogens
and epithelial ovarian cancer. Gynecol Oncol. 94:25–32. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park SH, Cheung LW, Wong AS and Leung PC:
Estrogen regulates Snail and Slug in the down-regulation of
E-cadherin and induces metastatic potential of ovarian cancer cells
through estrogen receptor alpha. Mol Endocrinol. 22:2085–2098.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hua K, Din J, Cao Q, Feng W, Zhang Y, Yao
L, Huang Y, Zhao Y and Feng Y: Estrogen and progestin regulate
HIF-1α expression in ovarian cancer cell lines via the activation
of Akt signaling transduction pathway. Oncol Rep. 21:893–898.
2009.PubMed/NCBI
|
|
8
|
Hua K, Feng W, Cao Q, Zhou X, Lu X and
Feng Y: Estrogen and progestin regulate metastasis through the
PI3K/AKT pathway in human ovarian cancer. Int J Oncol. 33:959–967.
2008.PubMed/NCBI
|
|
9
|
Ding JX, Feng YJ, Yao LQ, Yu M, Jin HY and
Yin LH: The reinforcement of invasion in epithelial ovarian cancer
cells by 17 beta-Estradiol is associated with up-regulation of
Snail. Gynecol Oncol. 103:623–630. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spillman MA, Manning NG, Dye WW, Sartorius
CA, Post MD, Harrell JC, Jacobsen BM and Horwitz KB:
Tissue-specific pathways for estrogen regulation of ovarian cancer
growth and metastasis. Cancer Res. 70:8927–8936. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Laviolette LA, Garson K, Macdonald EA,
Senterman MK, Courville K, Crane CA and Vanderhyden BC:
17beta-estradiol accelerates tumor onset and decreases survival in
a transgenic mouse model of ovarian cancer. Endocrinology.
151:929–938. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O'Donnell AJ, Macleod KG, Burns DJ, Smyth
JF and Langdon SP: Estrogen receptor-alpha mediates gene expression
changes and growth response in ovarian cancer cells exposed to
estrogen. Endocr Relat Cancer. 12:851–866. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gutschner T, Hämmerle M, Eissmann M, Hsu
J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al:
The noncoding RNA MALAT1 is a critical regulator of the metastasis
phenotype of lung cancer cells. Cancer Res. 73:1180–1189. 2013.
View Article : Google Scholar
|
|
14
|
Du Y, Kong G, You X, Zhang S, Zhang T, Gao
Y, Ye L and Zhang X: Elevation of highly up-regulated in liver
cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell
proliferation via down-regulating p18. J Biol Chem.
287:26302–26311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gupta RA, Shah N, Wang KC, Kim J, Horlings
HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matouk IJ, DeGroot N, Mezan S, Ayesh S,
Abu-lail R, Hochberg A and Galun E: The H19 non-coding RNA is
essential for human tumor growth. PLoS One. 2:e8452007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huarte M, Guttman M, Feldser D, Garber M,
Koziol MJ, Kenzelmann-Broz D, Khalil AM, Zuk O, Amit I, Rabani M,
et al: A large intergenic noncoding RNA induced by p53 mediates
global gene repression in the p53 response. Cell. 142:409–419.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou Y, Zhang X and Klibanski A: MEG3
noncoding RNA: A tumor suppressor. J Mol Endocrinol. 48:R45–R53.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qiao HP, Gao WS, Huo JX and Yang ZS: Long
non-coding RNA GAS5 functions as a tumor suppressor in renal cell
carcinoma. Asian Pac J Cancer Prev. 14:1077–1082. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang J, Sun CC and Gong C: Long noncoding
RNA XIST acts as an oncogene in non-small cell lung cancer by
epigenetically repressing KLF2 expression. Biochem Biophys Res
Commun. 478:811–817. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Yu H, Xi M and Lu X: Long noncoding
RNA C17orf91 is a potential prognostic marker and functions as an
oncogene in ovarian cancer. J Ovarian Res. 9:492016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liao T, Qu N, Shi RL, Guo K, Ma B, Cao YM,
Xiang J, Lu ZW, Zhu YX, Li DS, et al: BRAF-activated LncRNA
functions as a tumor suppressor in papillary thyroid cancer.
Oncotarget. 8:238–247. 2017.
|
|
23
|
Sang Y, Zhou F, Wang D, Bi X, Liu X, Hao
Z, Li Q and Zhang W: Up-regulation of long non-coding HOTTIP
functions as an oncogene by regulating HOXA13 in non-small cell
lung cancer. Am J Transl Res. 8:2022–2032. 2016.PubMed/NCBI
|
|
24
|
Tanos V, Prus D, Ayesh S, Weinstein D,
Tykocinski ML, De-Groot N, Hochberg A and Ariel I: Expression of
the imprinted H19 oncofetal RNA in epithelial ovarian cancer. Eur J
Obstet Gynecol Reprod Biol. 85:7–11. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rangel LB, Sherman-Baust CA, Wernyj RP,
Schwartz DR, Cho KR and Morin PJ: Characterization of novel human
ovarian cancer-specific transcripts (HOSTs) identified by serial
analysis of gene expression. Oncogene. 22:7225–7232. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Silva JM, Boczek NJ, Berres MW, Ma X and
Smith DI: LSINCT5 is over expressed in breast and ovarian cancer
and affects cellular proliferation. RNA Biol. 8:496–505. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Qiu JJ, Wang Y, Liu YL, Zhang Y, Ding JX
and Hua KQ: The long non-coding RNA ANRIL promotes proliferation
and cell cycle progression and inhibits apoptosis and senescence in
epithelial ovarian cancer. Oncotarget. 7:32478–32492.
2016.PubMed/NCBI
|
|
28
|
Qiu JJ, Lin YY, Ye LC, Ding JX, Feng WW,
Jin HY, Zhang Y, Li Q and Hua KQ: Overexpression of long non-coding
RNA HOTAIR predicts poor patient prognosis and promotes tumor
metastasis in epithelial ovarian cancer. Gynecol Oncol.
134:121–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chooniedass-Kothari S, Vincett D, Yan Y,
Cooper C, Hamedani MK, Myal Y and Leygue E: The protein encoded by
the functional steroid receptor RNA activator is a new modulator of
ER alpha transcriptional activity. FEBS Lett. 584:1174–1180. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bhan A and Mandal SS: Estradiol-induced
transcriptional regulation of Long non-coding RNA, HOTAIR. Methods
Mol Biol. 1366:395–412. 2016. View Article : Google Scholar
|
|
31
|
Xue X, Yang YA, Zhang A, Fong KW, Kim J,
Song B, Li S, Zhao JC and Yu J: LncRNA HOTAIR enhances ER signaling
and confers tamoxifen resistance in breast cancer. Oncogene.
35:2746–2755. 2016. View Article : Google Scholar :
|
|
32
|
Qiu J, Ye L, Ding J, Feng W, Zhang Y, Lv
T, Wang J and Hua K: Effects of oestrogen on long noncoding RNA
expression in oestrogen receptor alpha-positive ovarian cancer
cells. J Steroid Biochem Mol Biol. 141:60–70. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang Y, Wang Z, Qi Z, Yin S, Zhang N, Liu
Y, Liu M, Meng J, Zang R, Zhang Z, et al: The negative interplay
between Aurora A/B and BRCA1/2 controls cancer cell growth and
tumorigenesis via distinct regulation of cell cycle progression,
cytokinesis, and tetraploidy. Mol Cancer. 13:942014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin CY, Vega VB, Thomsen JS, Zhang T, Kong
SL, Xie M, Chiu KP, Lipovich L, Barnett DH, Stossi F, et al:
Whole-genome cartography of estrogen receptor alpha binding sites.
PLoS Genet. 3:e872007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kushner PJ, Agard DA, Greene GL, Scanlan
TS, Shiau AK, Uht RM and Webb P: Estrogen receptor pathways to
AP-1. J Steroid Biochem Mol Biol. 74:311–317. 2000. View Article : Google Scholar
|
|
36
|
Carroll JS, Meyer CA, Song J, Li W,
Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK, Fertuck KC,
Hall GF, et al: Genome-wide analysis of estrogen receptor binding
sites. Nat Genet. 38:1289–1297. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang Y, Li X and Muyan M: Estrogen
receptors similarly mediate the effects of 17β-estradiol on
cellular responses but differ in their potencies. Endocrine.
39:48–61. 2011. View Article : Google Scholar
|
|
38
|
Lee M, Kim HJ, Kim SW, Park SA, Chun KH,
Cho NH, Song YS and Kim YT: The long non-coding RNA HOTAIR
increases tumour growth and invasion in cervical cancer by
targeting the Notch pathway. Oncotarget. 7:44558–44571.
2016.PubMed/NCBI
|
|
39
|
Luo G, Wang M, Wu X, Tao D, Xiao X, Wang
L, Min F, Zeng F and Jiang G: Long non-coding RNA MEG3 inhibits
cell proliferation and induces apoptosis in prostate cancer. Cell
Physiol Biochem. 37:2209–2220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Herrera-Abreu MT, Palafox M, Asghar U,
Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M,
Rodriguez O, Grueso J, et al: Early adaptation and acquired
resistance to CDK4/6 inhibition in estrogen receptor-positive
breast cancer. Cancer Res. 76:2301–2313. 2016. View Article : Google Scholar : PubMed/NCBI
|
